M

Seres Therapeutics
D

MCRB

0.91030
USD
0.03
(3.80%)
Market Closed
Volume
38,662
EPS
-0
Div Yield
-
P/E
-2
Market Cap
155,422,864
Related Instruments
    A
    ALLO
    -0.19000
    (-7.71%)
    2.27500 USD
    B
    BEAM
    -2.275
    (-8.65%)
    24.035 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    More
News

Title: Seres Therapeutics

Sector: Healthcare
Industry: Biotechnology
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by thecompany are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.